In conclusion, the novel FABP5 inhibitor dmrFABP5 suppresses the malignant progression of CRPC by blocking fatty acid-stimulation of PPARγ and thereby it curtails its up- or down-regulating effect on the down-stream cancer-promoting or -suppressing genes in the nude mouse model of CRPC. Here, PPARG is linked to cancer.